Yahoo! Finance Search - Finance Home - Yahoo! - Help

Wednesday, March 4 2015 3:34am ET - U.S. Markets open in 5 hours and 56 minutes.
Industry Center - Drug Manufacturers - Other
Industry Center > Drug Manufacturers - Other > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drug Manufacturers - Other News
Latest News
Tuesday, Mar 3, 2015
·Report: Orexigen Therapeutics Jumped Gun On Contrave Heart Study
- Tue 9:07 pm ET
·PRESS DIGEST- Financial Times - Mar 4
Reuters - Tue 7:54 pm ET
·Insys Therapeutics Q4 beats
Investor's Business Daily, Inc. - Tue 6:32 pm ET
·Cumberland posts 4Q profit
AP - Tue 5:46 pm ET
·Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones
PR Newswire - Tue 5:30 pm ET
·Orexigen Comments On Data Disclosure That "Disappointed" FDA
at Forbes.com - Tue 4:13 pm ET
·Cumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014
PR Newswire - Tue 4:05 pm ET
·Amarin Reports Fourth Quarter and Year-End 2014 Financial Results and Provides Update on Operations
Marketwire - Tue 4:00 pm ET
·The FDA Is Forcing Orexigen To Do A Second Safety Study Because Of Contrave Disclosures
at Forbes.com - Tue 3:33 pm ET
·Orexigen Released Interim Data Without Approval Of Trial Leaders
at Forbes.com - Tue 2:06 pm ET
·Key Analyst Weighs In on Boston Scientific Acquisition
- Tue 12:25 pm ET
·Actavis's $21bn bond sale is second-largest on record
at FT.com - Tue 12:17 pm ET
·Insys Therapeutics Q4 Beat Drives Short-Lived Rally
at Investor's Business Daily, Inc. - Tue 11:46 am ET
·Lawmakers Pressure Amphastar Over Price Hikes for its Heroin Antidote
at The Wall Street Journal Online - Tue 11:11 am ET
·Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases
PR Newswire - Tue 9:00 am ET
·AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection
PR Newswire - Tue 8:45 am ET
·Depomed To Present At 27th Annual Roth Conference
PR Newswire - Tue 8:00 am ET
·Boston Scientific to Halt Buybacks for Deal
at Barrons.com - Tue 7:05 am ET
·Sucampo Announces Webcast of Its Presentation at the 27th Annual ROTH Conference
GlobeNewswire - Tue 6:45 am ET
Monday, Mar 2, 2015
·What Are The Real Economic Costs Of Obesity?
at Investopedia - Mon 6:05 pm ET
More Latest News...
Sponsor Results
MUSA Technology Services
BioTech/ Pharma/ MedDev /Healthcare GMP, GCP, GLP, Validation, HIPAA
www.musatechnology.com/
Comprehensive R&D
Antimicrobial and microbiology services with decades of expertise.
dptlabs.com
Two Best Biotech Stocks
Here's Why These Little-Known Firms Will Change The World. More Here.
wealthdaily.com/Biotech_Stocks
(What's This?)
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Other Headlines
More Finance RSS Feeds


Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2015 Morningstar, Inc. All Rights Reserved. Company information © 2015 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2015, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?